GlassScriptPhysician profile
Jodi Lynette Sanson
NPI 1770538308
$8,894.31
in general payments reported to CMS, 2019-2025
60 companies · $1,415 in 2025
The $1,415 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,094 · 2020: $922 · 2021: $1,384 · 2022: $1,217 · 2023: $1,532 · 2024: $1,330 · 2025: $1,415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,276.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,454.36 | 2020-2025 | Ubrelvy, Qulipta, Vraylar |
| Glaxosmithkline, LLC. | $656.31 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $652.71 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $563.99 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Otsuka America Pharmaceutical, INC. | $496.05 | 2020-2025 | Rexulti, Abilify Maintena |
| Antares Pharma, INC. | $377.41 | 2020-2025 | Xyosted |
| Astellas Pharma US INC | $367.11 | 2019-2024 | Veozah |
| Abbott Laboratories | $363.17 | 2020-2025 | Freestyle Libre 3, Cardiomems |
| Novo Nordisk INC | $357.07 | 2019-2024 | Ozempic, Rybelsus |
| Horizon Therapeutics Plc | $294.96 | 2019-2022 | |
| Allergan, INC. | $207.13 | 2019-2020 | |
| Axsome Therapeutics, INC. | $197.15 | 2023-2025 | Auvelity |
| Amgen INC. | $195.71 | 2019-2025 | Repatha, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $171.33 | 2019-2025 | Xifaxan, Trulance |
| Biohaven Pharmaceuticals, INC. | $166.72 | 2021 |
Show all 59 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jodi Sanson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.